News

Cupron Performance Additives (“Cupron”) announces new distribution relationship with Palmer Holland

Cupron Performance Additives (Cupron) announced today the launch of an exclusive distribution agreement with Palmer Holland, leading North American distributor of specialty additives for the engineered materials marketplace. Palmer Holland will distribute Cupron’s copper-based antimicrobial and anti-odor technologies into plastics, films, foams, and polymeric systems throughout North America. The Cupron line effectively complements Palmer Holland’s already best-in-class portfolio of specialty additives for plastics.

The Cupron/Palmer Holland partnership offers customers immediate value backed by cutting-edge science and renowned service. Palmer Holland’s deep knowledge of plastic, film, and foam applications will combine synergistically with Cupron’s most time-tested, well-proven antimicrobial and anti-odor technologies. Cupron products are available now for purchase and sampling from Palmer Holland.

Commenting on the partnership, Chris Andrews, Cupron’s Chief Executive Officer, said,

“We were drawn to Palmer Holland’s reputation for its longstanding differentiated market service. Extensive due diligence only validated our assumptions. Where it matters most, our companies overlap in culture and market objectives. Our thanks to Palmer Holland’s talented sales professionals for their vision and enthusiasm during scale-up discussions. We send gratitude and congratulations to Palmer Holland leaders Vince Misiti, Tony Denton, and Jim Norris for their stewardship of a truly great organization.”

Jim Norris, Market Manager for Engineered Materials at Palmer Holland, commented,

“Palmer Holland’s Engineered Materials Business continues to set itself apart with a distribution model designed to deliver unmatched value to suppliers and customers alike. Our new partnership with Cupron is a perfect fit with our strategy of championing specialty additives and modifiers that redefine performance standards. Cupron brings to the plastic-adjacent market a one-of-a-kind technology that combines proven antimicrobial, biocidal, and antifungal protection with a strong sustainability profile—addressing critical needs in product safety, durability, and environmental responsibility.

Through this collaboration, Palmer Holland will connect Cupron’s innovation with leading compounders and masterbatch producers, enabling the creation of next-generation materials that perform better, last longer, and contribute to a healthier planet.”

 

Read more here.

Recent News

03/17/2026

W&M Undergrads expand the chemical toolbox for cancer drugs

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like

03/17/2026

AgroSpheres and Wilbur-Ellis® Announce California Approval of FUN-THYME™

AgroSpheres and Wilbur-Ellis today announced that FUN-THYME, a broad-spectrum biofungicide co-developed by the two companies, has been approved for use in California. With demonstrated effectiveness on grapes, berries, apples, cherries, tomatoes and almonds, the new registration unlocks access for California growers. As the largest specialty crop producer in the United States, California is a defining

03/16/2026

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid b oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $35.75